D
Aldeyra Therapeutics, Inc. ALDX
$1.84 $0.41529.23%
Recommendation
Sell
Prev Close
$1.42
Volume
8,966,674
Avg Vol (90D)
803,326
Market Cap
$84.79M
Dividend & Yield
--
52-Week Range
$1.14 - $7.20
P/E (TTM)
--
EPS (TTM)
-$0.9388
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Fair
Volatility Index
Weak
Dividend Index
--
Headlines
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. ALDX
4/3/2025 - Globe Newswire
Small cap wrap: Excellon Resources, Trust Stamp, Aldeyra Therapeutics...
4/3/2025 - Proactive Investors - UK
Noteworthy Thursday Option Activity: SOC, ALDX, AFRM
4/3/2025 - Stock Options Channel
ALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. ...
4/3/2025 - GuruFocus
ALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA Law
4/3/2025 - Business Wire
BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud ...
4/3/2025 - GuruFocus
ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. ...
4/3/2025 - GuruFocus
ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock Drop Triggers Securities Investigation; Contact BFA Law if You Lost Money (NASDAQ:ALDX)
4/3/2025 - Globe Newswire
Aldeyra Stock Slumps After FDA Says Investigational Drug For Dry Eyes Treatment Failed To Demonstrate Efficacy Retail Stays Optimistic
4/3/2025 - Stocktwits News Feed
BREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud After Shares Fall Nearly 75%; Investors Encouraged to Contact the Firm
4/3/2025 - Globe Newswire
Aldeyra Therapeutics tanks as FDA rejects investigational dry eye disease therapy
4/3/2025 - Proactive Investors - UK
Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter
4/3/2025 - Investopedia Headlines
Aldeyra Therapeutics (ALDX) Plummets 74% After FDA Rejection
4/3/2025 - GuruFocus
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. ...
4/3/2025 - GuruFocus
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
4/3/2025 - Business Wire
The volume for Aldeyra Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 216% of the 65-Day Volume Moving Average
4/3/2025 - Tickeron - Stocks
Aldeyra Therapeutics (ALDX, $5.33) Stochastic Oscillator left the oversold zone on April 02, 2025
4/3/2025 - Tickeron - Stocks
aldeyras dry eye drug suffers second fda rejection imminent readout spurs hope fast
4/3/2025 - FierceBiotech.com - Biotech
Aldeyra Therapeutics (ALDX, $5.75) price exceeded its 50-day Moving Average on March 31, 2025
4/1/2025 - Tickeron - Stocks
Aldeyra Therapeutics (ALDX, $6.26) Stochastic Oscillator left the oversold zone on March 27, 2025
3/28/2025 - Tickeron - Technical Analysis
Raymond James Financial Inc. Invests $3.63 Million in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)
3/28/2025 - MarketBeat
Aldeyra Therapeutics (ALDX, $6.61) entered Downtrend as Momentum indicator drops below 0 level on Mar 24, 2025
3/25/2025 - Tickeron - Stocks
Aldeyra Therapeutics (ALDX, $6.31) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 17, 2025
3/18/2025 - Tickeron - Stocks
Aldeyra Therapeutics (ALDX, $6.92) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 11, 2025
3/12/2025 - Tickeron - Stocks
Aldeyra Therapeutics (ALDX, $6.62) entered Uptrend as Momentum indicator ascends above 0 level on Mar 10, 2025
3/11/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$59.87M
EBIT (TTM)
-$60.12M
Net Income (TTM)
-$55.85M
Balance Sheet
Total Assets (Q)
$104.61M
Total Debt (Q)
$15.30M
Total Liabilities (Q)
$33.60M
Book Value Per Share (Q)
$1.19
Cash Flow
Cash from Operations (TTM)
-$43.21M
Cash from Investing (TTM)
-$44.92M
Cash from Financing (TTM)
-$171.40K
Net Change in Cash (TTM)
-$88.30M
Filings
Filing Date
Friday, February 28, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Beginning of May (est)
Price History
Loading...
Beta
3.15
7-Day Total Return
-70.87%
30-Day Total Return
-72.57%
60-Day Total Return
-64.09%
90-Day Total Return
-61.85%
Year to Date Total Return
-64.85%
1-Year Total Return
-60.83%
2-Year Total Return
-81.50%
3-Year Total Return
-62.16%
5-Year Total Return
-20.91%
52-week Low
Apr 03, 2025 - $1.14
52-week High
Mar 12, 2025 - $7.20
Valuation
Market Cap
$84.79M - Micro Cap
Enterprise Value
-$1.06M
Price/Sales (TTM)
--
Price/Book (Q)
1.19
Dividends and Shares
Shares Outstanding
59.58M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.aldeyra.com
Phone Number
781 761 4904
Address
131 Hartwell Avenue
Lexington, MA 02421
Country
United States
Year Founded
2004
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a... more
NASDAQ 04/04/2025 12:38PM Eastern Quotes delayed
Weiss Ratings